Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
journal contributionposted on 2021-12-08, 17:41 authored by Ruben G. G. Leenders, Shoshy Alam Brinch, Sven T. Sowa, Enya Amundsen-Isaksen, Albert Galera-Prat, Sudarshan Murthy, Sjoerd Aertssen, Johannes N. Smits, Piotr Nieczypor, Eddy Damen, Anita Wegert, Marc Nazaré, Lari Lehtiö, Jo Waaler, Stefan Krauss
Tankyrase 1 and 2 (TNKS1/2) catalyze post-translational modification by poly-ADP-ribosylation of a plethora of target proteins. In this function, TNKS1/2 also impact the WNT/β-catenin and Hippo signaling pathways that are involved in numerous human disease conditions including cancer. Targeting TNKS1/2 with small-molecule inhibitors shows promising potential to modulate the involved pathways, thereby potentiating disease intervention. Based on our 1,2,4-triazole-based lead compound 1 (OM-1700), further structure–activity relationship analyses of East-, South- and West-single-point alterations and hybrids identified compound 24 (OM-153). Compound 24 showed picomolar IC50 inhibition in a cellular (HEK293) WNT/β-catenin signaling reporter assay, no off-target liabilities, overall favorable absorption, distribution, metabolism, and excretion (ADME) properties, and an improved pharmacokinetic profile in mice. Moreover, treatment with compound 24 induced dose-dependent biomarker engagement and reduced cell growth in the colon cancer cell line COLO 320DM.
Read the peer-reviewed publication
showed picomolar icreduced cell growthoverall favorable absorptionimproved pharmacokinetic profileeast -, southdependent biomarker engagementhippo signaling pathwayshybrids identified compound24 </ b50 </ sub2 also impactbased lead compound1 </ btranslational modificationtarget proteinstarget liabilitiespoint alterationsinvolved pathwaysinduced dosecatalyze post1700 ),153 ).